Key Takeaways
- Genvor, Inc. has appointed Donald Kalkofen as its new Chief Financial Officer, tasked with leading financial strategy across the company's agriculture and human health platforms.
- Kalkofen brings over 20 years of CFO experience in biotechnology, financial services, and technology, with a history of guiding companies through IPOs and complex capital markets transactions.
- His most recent CFO role was at Alpha Cognition, Inc., a NASDAQ-listed CNS-focused biotechnology company, where he led preparations for its public listing and built out investor relations and audit functions.
- Earlier roles include CFO positions at Protagonist Therapeutics and Symantec Corporation, as well as West Coast Bancorp, which he took public on NASDAQ and helped grow from $90 million to $1.5 billion in assets.
- Genvor is an AI-driven biotechnology company developing novel peptides for applications in both agriculture and human health and wellness.
Genvor Names Experienced Biotech CFO to Drive Financial Strategy
Genvor, Inc. (OTCQB: GNVR) has brought on Donald Kalkofen as Chief Financial Officer, the company announced. Kalkofen will oversee Genvor's financial operations as the biotechnology firm progresses its commercialization plans across two markets: agriculture and human health and wellness. Genvor uses artificial intelligence to develop novel peptides targeting both sectors.
Kalkofen's Background: IPOs, Capital Markets, and Biotech Growth
Kalkofen's career spans more than two decades in CFO roles across biotechnology, financial services, and technology companies. At Alpha Cognition, Inc., a publicly traded neurodegenerative disease-focused biotech, he led the company's NASDAQ listing preparations and established banking, audit committee, and investor relations functions. Prior to that, he served as CFO of Protagonist Therapeutics, a clinical-stage biopharmaceutical company, where he supported growth and oversaw a successful SOX 404(b) implementation.
Earlier in his career, Kalkofen held senior finance roles at Symantec Corporation and West Coast Bancorp, where he led the bank's NASDAQ listing and oversaw asset growth from $90 million to $1.5 billion.
What the Appointment Means for Genvor
“Don's track record of guiding biotechnology companies through transformational growth makes him the ideal financial leader for Genvor at this stage of our development. His deep public company experience combined with his command of complex capital markets and partnership transactions positions him to support the structuring of future joint development agreements across both our agricultural and human health and wellness platforms,” said Chad Pawlak, Chief Executive Officer of Genvor.
Kalkofen on Joining Genvor
“Genvor is at an exciting inflection point with a proprietary peptide platform, an expanding pipeline, and a clear path to growth across two complementary markets. Having helped guide biotechnology companies through similar transitions, I look forward to working alongside Chad and the team to strengthen Genvor's financial foundation that will drive the company's next phase of growth,” said Mr. Kalkofen.
Kalkofen is a Certified Public Accountant (inactive) and holds a Bachelor of Arts in Accounting from Washington State University.
